First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $75, Implies 62% Upside
First Tracks Biotherapeutics, Inc. stock's average price target increased to $75 from $74.17 by 12 analysts, with a range of $57 to $110. This implies a 62% upside from the Nov. 3 closing price. All 12 analysts maintain a 'Buy' rating.
How this was made

The 30-second read
Market read
Analyst price target update for a micro‑cap biotech; limited immediate trading impact.
Timing
post-market today
Background
Analyst consensus price target for First Tracks Biotherapeutics, Inc. raised to $75, implying ~62% upside.
Market effects
none
none
none